Datapoint: Lilly Scores First-Ever Alopecia Areata Nod

With this week’s FDA approval, Eli Lilly and Incyte’s Olumiant is first-ever treatment for alopecia areata, an autoimmune disease that causes a severe form of hair loss. The JAK inhibitor was first approved in 2018 as a rheumatoid arthritis therapy. For the treatment of rheumatoid arthritis, Olumiant holds covered or better status for 61% of all insured lives. Just 11% of insured lives have preferred access to Olumiant.

SOURCE: MMIT Analytics, as of 6/15/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 13

Datapoint: Mississippi to Launch State-Run Exchange

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today